EFFECT OF OLIGONUCLEOTIDE (ODN) IMT504 IN A TYPE I DIABETES MODEL IN MICETIPO I EN RATONES

VERÓNICA CALVO; ALEJANDRO MONTANER; CARLOS LIBERTUN; VICTORIA LUX-LANTOS; MARÍA S. BIANCHI

Ciudad Autónoma de BUenos Aires

Congreso; XII Jornada de la Sociedad Argentina de Biología; 2010

Sociedad Argentina de Biología

We have previously shown that the oligonucleotide IMT504 induces a marked recovery of streptozotocin (STZ)-induced diabetes in male rats that correlates with early production of progenitor cell markers (Diabetologia (2010) 53:1184). Here we studied the effect of IMT504 on a type I diabetes model induced by multiple low doses of STZ. 6-8 week-old male BalbC mice were injected with STZ (ip, 40mg/kg) daily for 5 consecutive days or with saline (control, C). Normal glycemia (Glyc) is 149±13 mg/dl. Animals with Glyc ³ 250 mg/dl were considered diabetics and injected with daily IMT doses (20mg/kg/day, sc) for 10 days (STZ-IMT) or saline as control (STZ) (day 1). C mice were injected with the same IMT doses (C-IMT) too. Animals were submitted to another 5 doses of IMT starting on 21 and 36 days. Body weight and glycemia were recorded. At the end of the experiment, glucose tolerance tests (GTT) were performed (2g/kg BW glucose was injected ip, day 59). IMT treatment induced a marked Glyc decrease [day 66= C: 130±9 vs STZ-IMT: 278±46, p<0.01, STZ-IMT vs STZ: 557±20, p<0.01]. GTT showed a partial recovery in the STZ-IMT responsiveness [0 min= C: 117±11 vs STZ-IMT: 164±9, ns, C vs STZ: 309±53, p<0.05; 30 min= C: 292±51 vs STZ-IMT: 342±33, ns, C vs STZ: 488±36, p<0.05; 120 min C: 133±15 vs STZ-IMT: 352±28, p<0.05, C vs STZ: 472±52, p<0.05]. IMT promoted a transient body weight decrease in diabetic animals. IMT504 could improve the diabetic condition in this model of type I diabetes. (CONICET-ANPCYT-UBA)